Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).

Synonyms

Not Available

External IDs

ACE-041

Categories

UNII

EGC16R10V0

CAS number

1186210-24-1

Pharmacology

Indication: Not Available
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Dalantercept.
Abituzumab	The risk or severity of adverse effects can be increased when Abituzumab is combined with Dalantercept.
Abrilumab	The risk or severity of adverse effects can be increased when Dalantercept is combined with Abrilumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Dalantercept.
Adecatumumab	The risk or severity of adverse effects can be increased when Adecatumumab is combined with Dalantercept.
Aducanumab	The risk or severity of adverse effects can be increased when Aducanumab is combined with Dalantercept.
Afelimomab	The risk or severity of adverse effects can be increased when Afelimomab is combined with Dalantercept.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalantercept.
Alirocumab	The risk or severity of adverse effects can be increased when Alirocumab is combined with Dalantercept.
Amatuximab	The risk or severity of adverse effects can be increased when Amatuximab is combined with Dalantercept.

Additional Data Available

Extended Description

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

References

General References

Not Available

External Links

Wikipedia: ALK_inhibitor

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Advanced Solid Tumors / Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Advanced Adult Hepatocellular Carcinoma	1
2	Active Not Recruiting	Treatment	Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma	1
2	Completed	Treatment	Advanced Renal Cell Carcinoma	1
2	Completed	Treatment	Endometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Mucinous Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Transitional Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma	1
2	Completed	Treatment	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State: Not Available
Experimental Properties: Not Available

Taxonomy

Classification: Not classified

Drug created on May 20, 2019 08:39 / Updated on November 02, 2019 03:28